Gilead Sciences (GILD) News Today

Gilead Sciences, Inc. (NASDAQ: GILD) has received several favorable analyst signals, helping support the stock’s recent increase. The main catalysts are higher long-term earnings expectations, a Zacks “Strong Buy” upgrade and potential growth from the company’s HIV portfolio. However, insider selling remains a modest sentiment concern.

• Positive Sentiment: Zacks upgraded Gilead to “Strong Buy.” The upgrade indicates improving expectations for the biopharmaceutical company’s earnings outlook and could attract additional investor interest. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its 2027 and 2028 EPS forecasts. The firm increased estimates for every 2027 quarter, lifting full-year 2027 EPS to $9.36 from $9.30, and raised full-year 2028 EPS to $9.66 from $9.58. Q1 and Q2 2028 estimates were also increased to $2.15 and $2.31, respectively, signaling modestly stronger expected profitability. Gilead EPS Estimates Raised
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV offering. The first-of-its-kind single-tablet treatment is designed for underserved patients and could create a new growth opportunity, although sales uptake and competition will determine its ultimate financial contribution. Bixlenvo HIV Growth Opportunity
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The sale reduced his direct ownership by 2.53%, but it was conducted under a pre-arranged Rule 10b5-1 trading plan, making it a limited bearish signal rather than evidence of a change in business outlook. SEC Insider Trading Filing

Overall, the news flow is tilted positive for GILD: stronger analyst forecasts and a new HIV product provide the clearest reasons for the recent upward move, while the planned CEO sale is unlikely to materially change investor sentiment.